Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

RP1 combined with nivolumab demonstrated an overall response rate of 36% and complete response rate of 20%, with clinically meaningful activity across a broad range of anti-PD1 failed cutaneous melanoma settings observed, in an initial data snapshot from the first 75 patients in the IGNYTE clinical trial.